All News

AHA 2022: Chronic users of either e-cigarettes or traditional cigarettes had acute changes in cardiovascular function and performed worse on exercise stress testing than never users in new study.

Apixaban was associated with up to a 28% lower risk of GI bleeding vs the 3 other direct oral anticoagulants in the first large-scale comparative analysis.

RSV is back for the 2022-23 respiratory virus season and is unfamiliar to many. Click through this quick collection of myths already in circulation to prepare.

Your daily dose of clinical news you may have missed.

Semaglutide 2.4 mg (Wegovy) weight loss benefits in adolescents mirror those seen in adults, according to phase 3a trial findings presented at ObesityWeek® 2022.

The American Gastroenterological Association released its first medical guideline recommending prescription medications for weight loss in adults with obesity. A review, here.

ObesityWeek® 2022. Primary care clinicians report providing on average just 70% of a wide range of clinical weight management services, according to a new survey.

Your daily dose of clinical news you may have missed.

AHA 2022: An estimated 18% of Americans with heart disease reported using wearables, compared with 29% of the total US population.

Topline phase 3 trial data showed 81.8% efficacy for the maternal vaccine against severe RSV-related illness in infants from birth through first 90 days of life.

ObesityWeek 2022: Regardless of the number of obesity-related comorbidities, tirzepatide was associated with a greater reduction in body weight than placebo.

Use of telemedicine and home blood pressure monitoring may mitigate adverse impact on BP control during future large-scale emergencies, noted researchers.

Your daily dose of clinical news you may have missed.

ObesityWeek® 2022. Coagonism of the glucagon and GLP-1 receptors appears to result in greater weight loss than GLP-1 receptor agonism alone, study suggests.

ObesityWeek® 2022. Low awareness of antiobesity medications and concerns about cost, side effects revealed as barriers to wider uptake in a new study.

ObesityWeek 2022: Tirzepatide-induced weight reduction was associated with body composition improvements in adults with obesity/overweight, found analysis of SURMOUNT-1.

Your daily dose of clinical news you may have missed.

Black patients were also at significantly increased risk of stroke, bleeding, and mortality vs White patients 1 year following discharge.